Clinical Trials at the MSRC
Multiple sclerosis is the most common non-traumatic, disabling disease of young adults, with an estimated 1,000,000 people affected in the United States. There is no cure for MS, but every year improvements in treatment and understanding of the disease offer hope to those million people. The most important thing patients can do: try.
One of the ways that you can try, is by volunteering for a clinical trial at M-Health. Without the help of those currently living with MS, clinical research focused on providing long-term treatments would be impossible. Check out the ongoing clinical trials below to see how you can make a difference:
Short Title: Best Available Therapy Versus Autologous Hematpoietic Stem Cell Transplant (AHSCT) for Multiple Sclerosis (BEAT-MS)
The overall objective of this study is to compare the efficacy, safety, immunologic effect of AHSCT versus best available therapy (BAT) over 72 months in patients with relapsing MS and continued MS despite treatment with DMTs. Secondary and exploratory objectives will be assessed clinically by MRI and measurement of disability metrics. Overall safety and specific safety outcomes will be compared. As exploratory objectives, self-reported health status and quality of life, cost utility, and qualitative and quantitative differences in immune signatures will be compared.
This is a multi-center prospective rater-blinded randomized controlled trial of 156 participants comparing the treatment strategy of myeloablative and immunoablative therapy followed by AHSCT versus BAT for treatment resistant relapsing multiple sclerosis.
Eligibility
- Are age 18 to 55
- Have been diagnosed with relapsing multiple sclerosis (MS)
- Have had incomplete benefit (continued relapses or active MRI) while taking prescription medicine for MS within the last 3 years
BEAT-MS Contact
Emily Harper
[email protected]
(612) 624-8431
DELIVER-MS Contact
Beth Zander
[email protected]
(612) 624-6778
Short Title: Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (DELIVER-MS)
DELIVER-MS seeks to determine if beginning initial treatment with a disease modifying therapy (DMT) as compared to a escalating approach where increased potency of treatment is necessary and determined by the pathology of the individual’s MS. This will be measured by a comparison of brain volume loss over thirty-six months. Secondary metrics will track the efficacy of improving patient reported outcomes as well as safety and tolerability.
Patients will be enrolled in the study for a duration of three years. Patients and their physicians will subsequently choose which DMT best fits their situation.
The trial is limited to those who have not yet received DMT and under fifty-five years of age with a diagnosis of relapsing MS - and of those people who have experienced their first symptom in the last five years.
Eligibility
- Are age 18 to 55
- Experience symptoms within the last 5 years
- Have not previously been treated with any DMT